|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0018894,
umls-concept:C0039194,
umls-concept:C0085358,
umls-concept:C0152060,
umls-concept:C0167627,
umls-concept:C0185117,
umls-concept:C0205154,
umls-concept:C0856825,
umls-concept:C1306235,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1546857,
umls-concept:C1706438,
umls-concept:C2698600,
umls-concept:C2911684
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1999-5-6
|
|
pubmed:abstractText |
Brief treatment with alphaCD154 Ab has been shown to prevent acute graft versus host disease (aGvHD). We extend these data to show that in the absence of CD154 function, donor T cells are unable to expand or generate high level anti-host CTL activity. Using transgenic (Tg) alloreactive CD8+ T cells adoptively transferred into allogeneic recipients, we show that short-term expansion of the CD8+ Tg T cells occurred in the absence of Th cells, and this short-term expansion could be facilitated with an agonistic alphaCD40. While CD40 agonism could enhance short-term expansion, sustained expansion of CD8+ Tg T cells required bona fide CD154-expressing CD4+ alloreactive Th cells. While CD154 was necessary for CD8+ Tg T cell sustained expansion, IL-2 was also implicated as essential. These observations suggest alphaCD154 therapy in GvHD is effective because the treatment causes an abortive CD8 alloresponse leading to the exhaustion or deletion of alloreactive CD8+ clones preventing the development of disease.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
162
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4373-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10201970-Acute Disease,
pubmed-meshheading:10201970-Animals,
pubmed-meshheading:10201970-Antigens, CD40,
pubmed-meshheading:10201970-CD40 Ligand,
pubmed-meshheading:10201970-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10201970-Cytotoxicity, Immunologic,
pubmed-meshheading:10201970-Graft vs Host Disease,
pubmed-meshheading:10201970-Isoantigens,
pubmed-meshheading:10201970-Lymphocyte Activation,
pubmed-meshheading:10201970-Membrane Glycoproteins,
pubmed-meshheading:10201970-Mice,
pubmed-meshheading:10201970-Mice, Inbred C57BL,
pubmed-meshheading:10201970-Mice, Inbred DBA,
pubmed-meshheading:10201970-Mice, Knockout,
pubmed-meshheading:10201970-Mice, Transgenic,
pubmed-meshheading:10201970-Signal Transduction,
pubmed-meshheading:10201970-T-Lymphocyte Subsets,
pubmed-meshheading:10201970-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:10201970-T-Lymphocytes, Helper-Inducer
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.
|
|
pubmed:affiliation |
Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
